Today the U.S. Food and Drug Administration (FDA) has approved the first vaccine for Respiratory syncytial virus (RSV), a disease that is said to mimic mild and moderate cold and flu symptoms.
RSV burst onto the scene last year as cases of Covid-19 continued to trend lower as RSV reportedly started to take its place in some capacity. Mainstream media and leading health authorities were dubbing this a “tripledemic,” as you might recall. RSV in particular was being blamed for massive spike in child sicknesses and subsequent overflowing of hospitals.
Now the FDA has approved the first vaccine to GlaxoSmithKline Biologicals (GSK), called “Arexvy.”
FDA explained their approval in a press release:
Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV.
Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States.
Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, said
RSV is a highly contagious virus that causes infections of the lungs and breathing passages in individuals of all age groups. RSV circulation is seasonal, typically starting during the fall and peaking in the winter. In older adults, RSV is a common cause of lower respiratory tract disease (LRTD), which affects the lungs and can cause life-threatening pneumonia and bronchiolitis (swelling of the small airway passages in the lungs). According to the U.S. Centers for Disease Control and Prevention, each year in the U.S., RSV leads to approximately 60,000-120,000 hospitalizations and 6,000-10,000 deaths among adults 65 years of age and older.
The safety and effectiveness of Arexvy is based on the FDA’s analysis of data from an ongoing, randomized, placebo-controlled clinical study conducted in the U.S. and internationally in individuals 60 years of age and older. The main clinical study of Arexvy was designed to assess the safety and effectiveness of a single dose administered to individuals 60 years of age and older. Participants will remain in the study through three RSV seasons to assess the duration of effectiveness and the safety and effectiveness of repeat vaccination. Data for a single dose of Arexvy from the first RSV season of the study were available for the FDA’s analysis.
In this study, approximately 12,500 participants have received Arexvy and 12,500 participants have received a placebo. Among the participants who have received Arexvy and the participants who have received a placebo, the vaccine significantly reduced the risk of developing RSV-associated LRTD by 82.6% and reduced the risk of developing severe RSV-associated LRTD by 94.1%.
Among a subset of these clinical trial participants, the most commonly reported side effects by individuals who received Arexvy were injection site pain, fatigue, muscle pain, headache and joint stiffness/pain. Among all clinical trial participants, atrial fibrillation within 30 days of vaccination was reported in 10 participants who received Arexvy and 4 participants who received placebo.
In two other studies, approximately 2,500 participants 60 years of age and older received Arexvy. In one of these studies, in which some participants received Arexvy concomitantly with an FDA-approved influenza vaccine, two participants developed acute disseminated encephalomyelitis (ADEM), a rare type of inflammation that affects the brain and spinal cord, seven and 22 days, respectively, after receiving Arexvy and the influenza vaccine. One of the participants who developed ADEM died. In the other study, one participant developed Guillain-Barré syndrome (a rare disorder in which the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis) nine days after receiving Arexvy.
The FDA is requiring the company to conduct a postmarketing study to assess the signals of serious risks for Guillain-Barré syndrome and ADEM. In addition, although not an FDA requirement, the company has committed to assess atrial fibrillation in the postmarketing study.
This application was granted Priority Review designation.
The FDA granted approval of Arexvy to GlaxoSmithKline Biologicals.
AUTHOR COMMENTARY
It should be noted that other vaccine manufacturers and countries such as Australia have been pursuing RSV vaccines of their own, and in some cases three-in-one vaccines for Covid, flu, and RSV, courtesy of Moderna.
RSV, just like Covid, is another silly excuse and coverup for other diseases and deleterious health effects caused by crappy food and water, medications, EMFs; and especially the Covid death shots.
The likelihood of people even taking this is very low, now that the Covid War is over and people are fed-up with the government and medical establishment, save only a chunk of obedient order followers and elderly brainwashed by their televisions daily.
But ye are forgers of lies, ye are all physicians of no value.
Job 13:4
[7] Who goeth a warfare any time at his own charges? who planteth a vineyard, and eateth not of the fruit thereof? or who feedeth a flock, and eateth not of the milk of the flock? [8] Say I these things as a man? or saith not the law the same also? [9] For it is written in the law of Moses, Thou shalt not muzzle the mouth of the ox that treadeth out the corn. Doth God take care for oxen? [10] Or saith he it altogether for our sakes? For our sakes, no doubt, this is written: that he that ploweth should plow in hope; and that he that thresheth in hope should be partaker of his hope. (1 Corinthians 9:7-10).
The WinePress needs your support! If God has laid it on your heart to want to contribute, please prayerfully consider donating to this ministry. If you cannot gift a monetary donation, then please donate your fervent prayers to keep this ministry going! Thank you and may God bless you.
The “covid war” is over but not the genocide. Those already jabbed and boosted are scheduled for death soon or later if not sooner.
Fool me once, shame on you. Fool me twice, shame on me. Obviously RSV is the latest technique to finish off the over 60’s useless eaters. Bioweapon jabs, midazolam, remdesivir, ventilators and now RSV.